Compare IDEXX Laboratories, Inc. (IDXX) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Marqeta Inc — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Marqeta Inc trades at $17.48 (market cap $1.85B). The key difference: IDEXX Laboratories, Inc. is far larger — about 24× Marqeta Inc's market cap. Which is the better fit depends on your goals.
| IDXX | MQ | |
|---|---|---|
Market Cap | $44.48B | $1.85B |
Sector | Health | Technology |
52-Week High | $766.68 | $27.32 |
52-Week Low | $520.87 | $15.04 |
Enterprise Value | $45.38B | $1.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Marqeta (MQ) trades at $17.45, down slightly by 0.23% today. The stock shows a bullish technical signal with strong moving average support, though RSI levels indicate mixed momentum. Fundamentally, the company reported revenue of $624.88M in 2025 (source: company filing 2025) but a net loss of $13.93M, with profitability metrics like net margin at 0.33% remaining thin. A recent 1-for-4 reverse stock split was effective July 1, 2026 (source: Business Wire 2026-06-29), aimed at boosting the share price amid restructuring efforts.
The outlook is cautiously optimistic with analyst consensus price target at $19.00 (source: MarketBeat 2026), implying potential upside, but high valuation ratios (P/E 436.88) and ongoing profitability challenges pose risks. Investor sentiment is mixed, balancing growth initiatives in Europe against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
